Newark, California
United States
37
2025-11-27
29
2025-02-25
These are the the leading inventors for applications assigned to Protagonist Therapeutics, Inc.:
Protagonist Therapeutics, Inc. based in Newark, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE
#2 | 2025-11-06HEPCIDIN ANALOGUES AND USES THEREOF
#3 | 2024-07-11CONJUGATED HEPCIDIN MIMETICS
#4 | 2024-06-27CONJUGATED HEPCIDIN MIMETICS
#5 | 2024-06-27A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS
#6 | 2024-06-27 ✅ Patent 12,234,300 granted on 2025-02-25Conjugated hepcidin mimetics
#7 | 2024-05-30 ✅ Patent 12,269,856 granted on 2025-04-08Hepcidin analogues and uses thereof
#8 | 2024-05-30 ✅ Patent 12,478,617 granted on 2025-11-25LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR
#9 | 2024-02-29CONJUGATED HEPCIDIN MIMETICS
#10 | 2024-01-18CONJUGATED HEPCIDIN MIMETICS
#11 | 2023-04-27PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES
#12 | 2022-12-22 ✅ Patent 12,018,057 granted on 2024-06-25Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
#13 | 2022-11-03 ✅ Patent 11,807,674 granted on 2023-11-07Hepcidin analogues and uses thereof
#14 | 2022-08-11 ✅ Patent 12,552,836 granted on 2026-02-17PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES
#15 | 2022-06-09 ✅ Patent 11,939,361 granted on 2024-03-26Compositions of peptide inhibitors of Interleukin-23 receptor
#16 | 2021-12-02 ✅ Patent 11,840,581 granted on 2023-12-12α4β7 thioether peptide dimer antagonists
#17 | 2021-11-25 ✅ Patent 11,884,748 granted on 2024-01-30Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
#18 | 2021-08-26 ✅ Patent 11,845,808 granted on 2023-12-19Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
#19 | 2021-05-20 ✅ Patent 11,472,842 granted on 2022-10-18Analogues of hepcidin mimetics with improved in vivo half lives
#20 | 2021-01-14 ✅ Patent 11,041,000 granted on 2021-06-22Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
#21 | 2020-11-19 ✅ Patent 11,753,443 granted on 2023-09-12Conjugated hepcidin mimetics
#22 | 2020-10-01 ✅ Patent 11,111,272 granted on 2021-09-07α4α7 peptide monomer and dimer antagonists
#23 | 2019-11-07 ✅ Patent 10,941,183 granted on 2021-03-09Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
#24 | 2019-09-05 ✅ Patent 12,655,185 granted on 2026-06-16PEPTIDE INHIBITORS OF INTERLEUKIN-23 AND THEIR USE TO TREAT INFLAMMATORY DISEASES
#25 | 2019-06-20 ✅ Patent 10,501,515 granted on 2019-12-10Hepcidin analogues and uses thereof
#26 | 2019-06-20 ✅ Patent 10,442,846 granted on 2019-10-15Hepcidin analogues and uses thereof
#27 | 2019-03-14 ✅ Patent 10,278,957 granted on 2019-05-07Opioid agonist peptides and uses thereof
#28 | 2019-01-17 ✅ Patent 10,626,146 granted on 2020-04-21α4β7 thioether peptide dimer antagonists
#29 | 2018-04-19 ✅ Patent 10,301,371 granted on 2019-05-28Cyclic monomer and dimer peptides having integrin antagonist activity
#30 | 2018-04-12 ✅ Patent 10,059,744 granted on 2018-08-28α4β7 thioether peptide dimer antagonists
#31 | 2018-03-29 ✅ Patent 10,030,061 granted on 2018-07-24Hepcidin analogues and uses thereof
#32 | 2018-03-22 ✅ Patent 10,023,614 granted on 2018-07-17Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
#33 | 2018-03-22 ✅ Patent 10,035,824 granted on 2018-07-31Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
#34 | 2018-01-25 ✅ Patent 10,196,424 granted on 2019-02-05Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
#35 | 2017-11-16 ✅ Patent 10,407,468 granted on 2019-09-10Methods for synthesizing α4β7 peptide antagonists
#36 | 2016-08-04 ✅ Patent 9,822,157 granted on 2017-11-21Hepcidin analogues and uses thereof
#37 | 2016-06-02 ✅ Patent 9,809,623 granted on 2017-11-07α4β7 peptide monomer and dimer antagonists
Also check out Protagonist Therapeutics, Inc.'s (Newark, United States) applicant profile with 48 patent applications submitted.
336426 ⎘